Expose MASH [Formerly NASH]
Expose MASH [Formerly NASH]
Novo Nordisk
Why MASH Screening Matters: Preventing Fibrosis Progression
20 minutes Posted Dec 10, 2024 at 9:21 pm.
0:00
20:22
Download MP3
Show notes
Join us in this episode of Expose MASH, as our experts delve into a discussion focused on the importance of identifying and referring patients at risk for MASH with clinically significant fibrosis (≥F2). Our experts will discuss the liver specialist perspective on the urgency for specialty referral of appropriate patients, including the increased morbidity and mortality associated with advancing liver fibrosis. They will also provide an overview of the importance of multidisciplinary collaboration and highlight the key role of primary care providers and endocrinologists as the front line for identification of patients before MASH progresses to clinically significant fibrosis.